Table of Contents Author Guidelines Submit a Manuscript
Journal of Transplantation
Volume 2010 (2010), Article ID 957549, 8 pages
http://dx.doi.org/10.1155/2010/957549
Clinical Study

Thymoglobulin Induction Dosing Strategies in a Low-Risk Kidney Transplant Population: Three or Four Days?

1Division of Pharmacy Practice and Administration, University of Missouri-Kansas City, Kansas City, MO 64108, USA
2Department of Internal Medicine, Washington University School of Medicine, 660 S. Euclid Avenue Campus Box 8126, St. Louis, MO 63110, USA

Received 4 August 2010; Accepted 26 September 2010

Academic Editor: P. S. Randhawa

Copyright © 2010 Karen L. Hardinger et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Thymoglobulin Prescribing Information, Genzyme, Cambridge, Mass, USA, 2005.
  2. A. O. Gaber, M. R. First, R. J. Tesi et al., “Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation,” Transplantation, vol. 66, no. 1, pp. 29–37, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. D. C. Brennan, K. Flavin, J. A. Lowell et al., “A randomized, double-blinded comparison of thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients,” Transplantation, vol. 67, no. 7, pp. 1011–1018, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. I. A. Agha, J. Rueda, A. Alvarez et al., “Short course induction immunosuppression with thymoglobulin for renal transplant recipients,” Transplantation, vol. 73, no. 3, pp. 473–475, 2002. View at Google Scholar · View at Scopus
  5. V. R. Peddi, M. Bryant, P. Roy-Chaudhury, E. S. Woodle, and M. R. First, “Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients,” Transplantation, vol. 73, no. 9, pp. 1514–1518, 2002. View at Google Scholar · View at Scopus
  6. T. E. Starzl, N. Murase, K. Abu-Elmagd et al., “Tolerogenic immunosuppression for organ transplantation,” Lancet, vol. 361, no. 9368, pp. 1502–1510, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Stratta, A. K. Sundberg, A. C. Farney, M. S. Rohr, E. L. Hartmann, and P. L. Adams, “Experience with alternate-day thymoglobulin induction in pancreas transplantation with portal-enteric drainage,” Transplantation Proceedings, vol. 37, no. 8, pp. 3546–3548, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. W. Wong, N. Agrawal, M. Pascual et al., “Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation,” Transplant International, vol. 19, no. 8, pp. 629–635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Gurk-Turner, R. Airee, B. Philosophe, D. Kukuruga, C. Drachenberg, and A. Haririan, “Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients,” Transplantation, vol. 85, no. 10, pp. 1425–1430, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. R. B. Stevens, D. F. Mercer, W. J. Grant et al., “Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report,” Transplantation, vol. 85, no. 10, pp. 1391–1399, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. W. C. Goggins, M. A. Pascual, J. A. Powelson et al., “A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients,” Transplantation, vol. 76, no. 5, pp. 798–802, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Préville, M. Flacher, B. LeMauff et al., “Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model,” Transplantation, vol. 71, no. 3, pp. 460–468, 2001. View at Google Scholar · View at Scopus
  13. L. Murray, Ed., Drug Topics Red Book, Thomson PDR, Montvale, NJ, USA, 2009.
  14. D. C. Brennan, K. A. Garlock, G. G. Singer et al., “Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients,” Transplantation, vol. 64, no. 12, pp. 1843–1846, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. D. C. Brennan, K. A. Garlock, B. A. Lippmann et al., “Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy,” Journal of the American Society of Nephrology, vol. 8, no. 1, pp. 118–125, 1997. View at Google Scholar · View at Scopus
  16. L. C. Racusen, K. Solez, R. B. Colvin et al., “The Banff 97 working classification of renal allograft pathology,” Kidney International, vol. 55, no. 2, pp. 713–723, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, and D. Roth, “A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation,” Annals of Internal Medicine, vol. 130, no. 6, pp. 461–470, 1999. View at Google Scholar